Stryker has completed the previously announced acquisition of Inari Medical for a total equity value of nearly $4.9bn, marking a significant expansion into the venous thromboembolism (VTE) market.

The transaction brings together Inari's thrombectomy solutions with Stryker's neurovascular portfolio.

Last month, Stryker entered a definitive agreement to acquire all issued and outstanding shares of Inari Medical's common stock.

Stryker CEO and chair Kevin Lobo said: “The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio.

“We look forward to welcoming the talented Inari team to Stryker and working together to improve outcomes for patients worldwide.”

The tender offer by Stryker's wholly owned subsidiary, Eagle 1 Merger Sub, for all outstanding shares of Inari Medical expired on 18 February 2025.

Equiniti Trust Company, the tender offer depository, confirmed that 48,504,444 Inari shares, or approximately 81.69% of Inari's outstanding common stock, were tendered and not withdrawn before the deadline.

Stryker's Merger Sub has accepted all shares tendered for payment and will promptly settle the transactions.

On 19 February, Stryker proceeded with the acquisition through a merger following the tender offer's completion.

As a result of the merger, each share of Inari common stock not already owned by Inari, Stryker, or their subsidiaries, and not subject to appraisal rights, was converted into the right to receive $80 in cash per share.

With the merger finalised, Inari Medical now operates as a wholly owned subsidiary of Stryker.

Inari Medical is known for its mechanical thrombectomy solutions, including the FlowTriever System for pulmonary embolism treatment and the ClotTriever System for peripheral vessel thrombectomy.